Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of givinostat in non-ambulant Duchenne muscular dystrophy
NL-OMON60070Phase 3Recruiting
- Sponsor
- Italfarmaco
- Start
- Feb 2024
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Duchenne muscular dystrophy (DMD) comparing givinostat with placebo (2 arms). Primary endpoint: Change in PUL total score. Started Feb 2024; status: recruiting.
02
Drugs
givinostat
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NL-OMON60070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60070.